000 | 03411nam a22004937a 4500 | ||
---|---|---|---|
001 | sulb-eb0022263 | ||
003 | BD-SySUS | ||
005 | 20160413122239.0 | ||
007 | cr nn 008mamaa | ||
008 | 130417s2013 xxu| s |||| 0|eng d | ||
020 |
_a9781461453802 _9978-1-4614-5380-2 |
||
024 | 7 |
_a10.1007/978-1-4614-5380-2 _2doi |
|
050 | 4 | _aQR180-189.5 | |
072 | 7 |
_aMJCM _2bicssc |
|
072 | 7 |
_aMED044000 _2bisacsh |
|
082 | 0 | 4 |
_a616.079 _223 |
245 | 1 | 0 |
_aNovel Immune Potentiators and Delivery Technologies for Next Generation Vaccines _h[electronic resource] / _cedited by Manmohan Singh. |
264 | 1 |
_aBoston, MA : _bSpringer US : _bImprint: Springer, _c2013. |
|
300 |
_aX, 370 p. _bonline resource. |
||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bc _2rdamedia |
||
338 |
_aonline resource _bcr _2rdacarrier |
||
347 |
_atext file _bPDF _2rda |
||
505 | 0 | _aCritical parameters that govern the optimization of vaccine formulations -- Development of Biophysical assays to better understand vaccine formulation stability -- Rational design of vaccine formulations -- Monitoring stability and efficacy of multi-valent vaccine formulations.- Overcoming challenges of multi component alum formulations.- Delivery of various TLR adjuvants using alum platform -- History of use of emulsions for vaccine delivery -- MF59 o/w emulsion : History and safety over the last 2 decades -- Optimizing novel nanoemulsions for delivery of next generation antigens and adjuvants -- Modulating vaccine responses with innate immunity : Use of PLGA nanoparticles for delivering multiple TLR agonists -- Shape matters : Role of nanoparticle shape in induction of immune responses to a vaccine. . | |
520 | _aDevelopment of new-generation vaccines is now more challenging than ever, as identifying, purifying and evaluating vaccine antigens is a complex undertaking. Most importantly, once the relevant antigens have been identified, key focus then shifts to the development of suitable delivery systems and formulations to achieve maximum in vivo potency with minimum potential side effects. These novel formulations—many of which will be nanoparticulates—can deliver the antigens to the desired site, to the relevant antigen presenting cells, and prevent systemic exposure of the immune potentiators. The proposed book will outline all the critical steps that need to be considered for successful development of various types of nanoparticulate delivery systems for vaccine antigens. These contributions from leading experts in the area of vaccine formulation and delivery systems will tie in what is the most current status, including clinical evaluations with these novel vaccine technologies. | ||
650 | 0 | _aMedicine. | |
650 | 0 | _aImmunology. | |
650 | 0 | _aMedical microbiology. | |
650 | 0 | _aVaccines. | |
650 | 0 | _aPharmaceutical technology. | |
650 | 1 | 4 | _aBiomedicine. |
650 | 2 | 4 | _aImmunology. |
650 | 2 | 4 | _aMedical Microbiology. |
650 | 2 | 4 | _aVaccine. |
650 | 2 | 4 | _aPharmaceutical Sciences/Technology. |
700 | 1 |
_aSingh, Manmohan. _eeditor. |
|
710 | 2 | _aSpringerLink (Online service) | |
773 | 0 | _tSpringer eBooks | |
776 | 0 | 8 |
_iPrinted edition: _z9781461453796 |
856 | 4 | 0 | _uhttp://dx.doi.org/10.1007/978-1-4614-5380-2 |
912 | _aZDB-2-SBL | ||
942 |
_2Dewey Decimal Classification _ceBooks |
||
999 |
_c44355 _d44355 |